Literature DB >> 26433736

Incidence of morphometric vertebral fractures in adult patients with growth hormone deficiency.

Gherardo Mazziotti1,2, Mauro Doga1, Stefano Frara1, Filippo Maffezzoni1, Teresa Porcelli1, Luigi Cerri1, Roberto Maroldi3, Andrea Giustina4.   

Abstract

Cross-sectional studies showed an elevated prevalence of clinical and morphometric vertebral fractures (VFs) in adult patients with growth hormone deficiency (GHD). However, no data are available on incidence and determinants of radiological VFs in this clinical setting. In this prospective study, we investigated the incidence and risk factors of radiological VFs in adults with GHD. Forty patients with GHD (28 males, 12 females; median age 44 years, range 19-82) were studied for incident VFs using quantitative morphometric approach on spine X-ray at baseline and after 6 years of follow-up. GHD patients were also studied for bone mineral density (BMD) measured by DXA at lumbar spine. After 6 years of follow-up, 12 patients (30 %) experienced incident VFs. Patients with incident VFs had more frequently untreated GHD and prevalent VFs at baseline, as compared to patients who did not experience incident VFs. Untreated GHD patients were significantly older as compared to treated GHD (50 years, range 19-82 vs. 36 years, range 19-75; p = 0.003), but the correlation between high risk of VFs and untreated GHD remained significant even after adjustment for the age of patients (odds ratio 6.8, CI 95 % 1.1-41.8; p = 0.037). In GHD patients experiencing incident VFs, lumbar spine BMD decreased significantly whereas it did not change in patients not developing VFs. This is the first prospective study confirming the hypothesis suggested by cross-sectional studies that untreated GHD may cause high risk of VFs in adult patients and that recombinant human GH treatment may effectively decrease such a risk.

Entities:  

Keywords:  Bone mineral density; Growth hormone deficiency; IGF-I; Osteoporosis; Vertebral fractures

Mesh:

Substances:

Year:  2015        PMID: 26433736     DOI: 10.1007/s12020-015-0738-z

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  37 in total

Review 1.  Drug-induced osteoporosis: mechanisms and clinical implications.

Authors:  Gherardo Mazziotti; Ernesto Canalis; Andrea Giustina
Journal:  Am J Med       Date:  2010-10       Impact factor: 4.965

Review 2.  New advances in imaging osteoporosis and its complications.

Authors:  James F Griffith; Harry K Genant
Journal:  Endocrine       Date:  2012-05-23       Impact factor: 3.633

3.  The influence of growth hormone deficiency, growth hormone replacement therapy, and other aspects of hypopituitarism on fracture rate and bone mineral density. .

Authors:  C Wüster; R Abs; B A Bengtsson; H Bennmarker; U Feldt-Rasmussen; E Hernberg-Ståhl; J P Monson; B Westberg; P Wilton
Journal:  J Bone Miner Res       Date:  2001-02       Impact factor: 6.741

Review 4.  New understanding and treatments for osteoporosis.

Authors:  G Mazziotti; J Bilezikian; E Canalis; D Cocchi; A Giustina
Journal:  Endocrine       Date:  2012-02       Impact factor: 3.633

5.  Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline.

Authors:  Mark E Molitch; David R Clemmons; Saul Malozowski; George R Merriam; Mary Lee Vance
Journal:  J Clin Endocrinol Metab       Date:  2011-06       Impact factor: 5.958

6.  Evaluation of diagnostic accuracy of insulin-like growth factor (IGF)-I and IGF-binding protein-3 in growth hormone-deficient children and adults using ROC plot analysis.

Authors:  Hugo R Boquete; Patricia G V Sobrado; Hugo L Fideleff; Ana M Sequera; Ana V Giaccio; Martha G Suárez; Gabriela F Ruibal; Mirta Miras
Journal:  J Clin Endocrinol Metab       Date:  2003-10       Impact factor: 5.958

Review 7.  Effects of recombinant human growth hormone therapy on bone mineral density in adults with growth hormone deficiency: a meta-analysis.

Authors:  Maya Barake; Anne Klibanski; Nicholas A Tritos
Journal:  J Clin Endocrinol Metab       Date:  2014-01-01       Impact factor: 5.958

8.  Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis The Study of Osteoporotic Fractures Research Group.

Authors:  H K Genant; M Jergas; L Palermo; M Nevitt; R S Valentin; D Black; S R Cummings
Journal:  J Bone Miner Res       Date:  1996-07       Impact factor: 6.741

Review 9.  Executive summary of the 2013 International Society for Clinical Densitometry Position Development Conference on bone densitometry.

Authors:  John T Schousboe; John A Shepherd; John P Bilezikian; Sanford Baim
Journal:  J Clin Densitom       Date:  2013 Oct-Dec       Impact factor: 2.617

10.  Lifetime, untreated isolated GH deficiency due to a GH-releasing hormone receptor mutation has beneficial consequences on bone status in older individuals, and does not influence their abdominal aorta calcification.

Authors:  Anita H O Souza; Maria I T Farias; Roberto Salvatori; Gabriella M F Silva; João A M Santana; Francisco A Pereira; Francisco J A de Paula; Eugenia H O Valença; Enaldo V Melo; Rita A A Barbosa; Rossana M C Pereira; Miburge B Gois-Junior; Manuel H Aguiar-Oliveira
Journal:  Endocrine       Date:  2013-11-23       Impact factor: 3.633

View more
  19 in total

1.  Skeletal health in adult growth hormone deficiency.

Authors:  Nicholas A Tritos
Journal:  Endocrine       Date:  2016-01-14       Impact factor: 3.633

2.  Skeletal fragility: an emerging complication of Ehlers-Danlos syndrome.

Authors:  Anna Maria Formenti; Mauro Doga; Stefano Frara; Marco Ritelli; Marina Colombi; Giuseppe Banfi; Andrea Giustina
Journal:  Endocrine       Date:  2018-12-15       Impact factor: 3.633

3.  Untreated adult GH deficiency is not associated with the development of metabolic risk factors: a long-term observational study.

Authors:  V Gasco; L Roncoroni; M Zavattaro; C Bona; A Berton; E Ghigo; M Maccario; S Grottoli
Journal:  J Endocrinol Invest       Date:  2019-08-22       Impact factor: 4.256

Review 4.  Risk of vertebral fractures in hypoparathyroidism.

Authors:  Anna Maria Formenti; Francesco Tecilazich; Raffaele Giubbini; Andrea Giustina
Journal:  Rev Endocr Metab Disord       Date:  2019-09       Impact factor: 6.514

5.  Recombinant growth hormone treatment, osteoporosis and fractures, more complicated than it seems!

Authors:  Maria Fleseriu
Journal:  Endocrine       Date:  2018-01-19       Impact factor: 3.633

Review 6.  Acromegalic osteopathy.

Authors:  G Mazziotti; F Maffezzoni; S Frara; A Giustina
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

Review 7.  Effects of growth hormone therapy on bone density and fracture risk in age-related osteoporosis in the absence of growth hormone deficiency: a systematic review and meta-analysis.

Authors:  Maya Barake; Asma Arabi; Nancy Nakhoul; Ghada El-Hajj Fuleihan; Sarah El Ghandour; Anne Klibanski; Nicholas A Tritos
Journal:  Endocrine       Date:  2017-10-13       Impact factor: 3.633

8.  Effects of pegvisomant and somatostatin receptor ligands on incidence of vertebral fractures in patients with acromegaly.

Authors:  Sabrina Chiloiro; Gherardo Mazziotti; Antonella Giampietro; Antonio Bianchi; Stefano Frara; Marilda Mormando; Alfredo Pontecorvi; Andrea Giustina; Laura De Marinis
Journal:  Pituitary       Date:  2018-06       Impact factor: 4.107

9.  Real-life management and outcome of thyroid carcinoma-related bone metastases: results from a nationwide multicenter experience.

Authors:  G Mazziotti; A M Formenti; M B Panarotto; E Arvat; A Chiti; A Cuocolo; M E Dottorini; C Durante; L Agate; S Filetti; F Felicetti; A Filice; L Pace; T Pellegrino; M Rodari; M Salvatori; C Tranfaglia; A Versari; D Viola; S Frara; A Berruti; A Giustina; R Giubbini
Journal:  Endocrine       Date:  2017-11-06       Impact factor: 3.633

10.  High-resolution-cone beam tomography analysis of bone microarchitecture in patients with acromegaly and radiological vertebral fractures.

Authors:  Filippo Maffezzoni; Michele Maddalo; Stefano Frara; Monica Mezzone; Ivan Zorza; Fabio Baruffaldi; Francesco Doglietto; Gherardo Mazziotti; Roberto Maroldi; Andrea Giustina
Journal:  Endocrine       Date:  2016-09-06       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.